Navigation Links
King and Pain Therapeutics Announce REMOXY(R) NDA Update
Date:7/7/2009

BRISTOL, Tenn. and SAN MATEO, Calif., July 7 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced that on July 2, 2009, King met with the US Food and Drug Administration (FDA) to discuss the Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). The outcome of this meeting provided King with a clear path forward to resubmit the REMOXY(R) NDA and to address all FDA comments in the Complete Response Letter.

King now anticipates the resubmission of the NDA could occur mid-year 2010. The Company believes the rate-limiting step is the generation of six-month stability data, and no new clinical trials are required. King remains committed to the development and commercialization of REMOXY(R), and looks forward to working closely with the FDA toward approval of the product.

About REMOXY(R)

REMOXY, an investigational drug, is a unique, long-acting oxycodone formulation for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, Pain Therapeutics received a Complete Response Letter from the FDA. Subsequent to the receipt of the Complete Response Letter, King assumed full control of all activities related to the development of REMOXY(R).

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangement
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
2. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. PTC Therapeutics Receives $2.6 Million in Government Grants
5. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
11. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The announced sales of three healthcare ... looking to expand in non-healthcare areas, says Kalorama Information. ... research firm says that  Siemens is the third largest ... of the IVD market , with 5.5 billion in ... composition would likely affect IVD market shares.  ...
(Date:11/26/2014)... PMG Research, Inc. announced today the formation of ... sites that provide clinical research services to pharmaceutical companies and ... its partnerships with large physician practices and integrated health systems. ... the Southeastern United States and spans over 60 physician practices. ... will be held by: Dr. Robert Holmes, MD, of PMG ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 The Pittcon ... its official conference and exposition mobile app, ... free download in the App Store for iOS and ... valuable resource tool before, during and after the event. ... details on exhibiting companies, technical sessions, Conferee Networking sessions ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is an in-depth research report on the Global ... report introduces Palmitic Acid, basic information, including definition, ... analysis, and news analysis, etc. , For ... Palmitic Acid market in China and ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Pittcon Releases 2015 Mobile App 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3
... N.C., Feb. 6 PPD, Inc. (Nasdaq:,PPDI) today announced ... independent contract research organization, or CRO, based in,Smolensk, Russia. ... in both Russia and Ukraine., One of the ... the,implementation of good clinical practice (GCP) in the former ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... upcoming BIO CEO & Investor,Conference on Tuesday, February 12, ... Center/North Room at the Waldorf-Astoria Hotel in New York, ... presentation can be accessed,under "Calendar of Events" in the ...
... Further Solidifies Netsmart as Leader in Behavioral Healthcare Solutions for ... ... GREAT RIVER, N.Y., Feb. 6 Netsmart Technologies, Inc.,a leading provider ... announced it has signed a contract to,provide comprehensive licensed software and ...
Cached Biology Technology:PPD to Acquire InnoPharm Ltd. 2PPD to Acquire InnoPharm Ltd. 3Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3
(Date:11/12/2014)... BEACH GARDENS, Fla. , Nov. 12, 2014 /PRNewswire/ ... solutions, announced today that its U.are.U ® fingerprint ... retail bakery chain in Central Mexico ... in June 2014 to eliminate payroll issues caused by ... Prior to installing the U.are.U fingerprint readers, Montparnasse relied ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
(Date:11/6/2014)... asset for a predator. Except when that predator runs so ... relative to its size, is the fastest creature on Earth. ... per second (at about five miles per hour). The fastest ... sprinting gold from the tiger beetle, a person would have ... beetle has a problem. At peak speeds, everything becomes a ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2The tiger beetle: Too fast to see 2
... It may not be obvious, but hearing two ... to bilingualism by birth. According to new findings in ... for Psychological Science, infants born to bilingual mothers (who ... preferences than infants born to mothers speaking only one ...
... Scorpion venom is notoriously poisonous ― but it might ... painkillers like morphine, a Tel Aviv University researcher claims. ... University,s Department of Plant Sciences is investigating new ways ... found in the venom of scorpions. These compounds have ...
... (Birgitta) of Sweden that has been kept in a shrine ... conducted at Uppsala University reveals that the two skulls, believed ... is not from maternally related individuals. Furthermore, dating show that ... and Catherine lived. The findings are published in the journal ...
Cached Biology News:Bilingual babies: The roots of bilingualism in newborns 2Pinch away the pain 2Pinch away the pain 3The putative skull of St. Bridget can be questioned 2
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
Reacts with methylated DNA from plants and vertebrates...
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Biology Products: